Transcenta Holding Limited (06628.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.1x

Market Cap

HKD 424.55M

MomentumView details →

1D Return

+1.49%

YTD Return

−51.65%

RSI (14)

43.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.1x

Market Cap

HKD 424.55M

RSI (14)

43.5

MomentumView details →

1D Return

+1.49%

YTD Return

−51.65%

ProfitabilityView details →

Gross Margin

23.15%

Net Margin

−2740.08%

EBITDA Margin

−2092.47%

ROE (TTM)

−32.96%

ROA (TTM)

−22.03%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−33.98%

EPS YoY

+31.43%

FCF YoY

+33.85%

Revenue CAGR 3Y

−58.58%

EPS CAGR 3Y

+33.33%

EBITDA YoY

+33.38%

EarningsView details →

EPS (Actual)

−HKD 0.19

EPS Surprise

64.48%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 0.53

Avg Surprise (4Q)

64.48%

Rev Surprise

−6.84%

Capital & dividendView details →

Debt/Equity

0.20x

Current Ratio

0.25x

Quick Ratio

0.19x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

7.43M

Net Income (TTM)

−203.72M

Op. CF (TTM)

−135.67M

Next earningsMar 31, 2027 →

Latest newsMore news →

Pharmaceutical company Yaojie Ankang (02617.HK) reported interim results for the six months ended June 2026, with revenue of RMB 35.46 million and a narrowed net loss of RMB 95.47 million, compared with a loss of RMB 123 million in the same period last year.9d ago

Transcenta Holding announced the sale of its CDMO assets to WuXi Biologics for RMB 190 million, excluding intellectual property related to its candidate drug pipeline and core biomanufacturing platform.29d ago

Similar companies

Rocket Pharmaceuticals, Inc.RCKT PureTech Health plcPRTC Compass Therapeutics, Inc.CMPX ProKidney Corp.PROK Fennec Pharmaceuticals Inc.FENC Benitec Biopharma Inc.BNTC Find similar companies →

Latest newsMore news →

Pharmaceutical company Yaojie Ankang (02617.HK) reported interim results for the six months ended June 2026, with revenue of RMB 35.46 million and a narrowed net loss of RMB 95.47 million, compared with a loss of RMB 123 million in the same period last year.9d ago Transcenta Holding announced the sale of its CDMO assets to WuXi Biologics for RMB 190 million, excluding intellectual property related to its candidate drug pipeline and core biomanufacturing platform.29d ago